All items in the Healthy Skepticism Library
All the 20545 items in the Healthy Skepticism Library are listed below in order of publication date with the most recent at the top. There are 100 items per page.
Page 162 of 206 pages ‹ First < 160 161 162 163 164 > Last ›
HSL2367
Nurok , M .
Conflict-of-interest policies
NEJM 2001 Mar 29;344:(13):1017
HSL2368
Topol , E J.
Conflict-of-interest policies
NEJM 2001 Mar 29;344:(13):1017
HSL2511
Topol E.
Conflict-of-interest policies (1st of 6 letters)
New England Journal of Medicine 2001 Mar 29;344:(13):1017
HSL2540
Ratain M.
Conflict-of-interest policies (3rd of 6 letters)
New England Journal of Medicine 2001 Mar 29;344:(13):1018
HSL2543
Nurok M.
Conflict-of-interest policies (2nd of 6 letters)
New England Journal of Medicine 2001 Mar 29;344:(13):1017
HSL2548
Miller F.
To protect those who serve (1st of 2 letters)
New England Journal of Medicine 2001 Mar 29;344:(13):1018-9
HSL2555
McCrary SV, McCullough LB, Brody BA.
Conflict-of-interest policies (5th of 6 letters)
New England Journal of Medicine 2001 Mar 29;344:(13):1018
HSL2556
Martin J, Kasper D.
Conflict-of-interest policies (6th of 6 letters)
New England Journal of Medicine 2001 Mar 29;344:(13):1018
HSL2558
Lo B, Wolf L.
Conflict-of-interest policies (4th of 6 letters)
New England Journal of Medicine 2001 Mar 29;344:(13):1018
HSL2566
Drazen J, Koski G.
To protect those who serve (2nd of 2 letters)
New England Journal of Medicine 2001 Mar 29;344:(13):1019
HSL2030
Dieperink ME, Drogemuller L.
Industry-sponsored grand rounds and prescribing behavior.
JAMA 2001 Mar 21;
http://jama.ama-assn.org/cgi/content/full/285/11/1443
HSL2020
Byrne M.
Drug makers to operate in a new market
Australian Financial Review 2001 Mar 14
HSL10212
Willman D.
Risk Was Known as FDA OK'd Fatal Drug
Los Angeles Times 2001 Mar 11
http://www.lef.org/magazine/mag2001/june2001_report_fda.html
HSL19533
Hall SS
Claritin and Schering-Plough: A Prescription for Profit
The New York Times 2001 Mar 11
http://www.nytimes.com/2001/03/11/magazine/11CLARITIN.html?pagewanted=all
HSL17979
Henry DA, Birkett DJ.
Changes to the Pharmaceutical Benefits Advisory Committee.
Med J Aust 2001 Mar 5;174:(5):209-10
http://www.mja.com.au/public/issues/174_05_050301/henry/henry.html
HSL20168
Silversides A
Under the counter: Pharmaceutical companies are pushing the boudnaries of the law against direct-to-consumer drug advertising
Eye Weekly 2001 Mar 5
http://contests.eyeweekly.com/eye/issue/issue_05.03.01/news/drugs.php
HSL5299
Marshall JN, Stewart M, Ostbye T.
Small-group CME using e-mail discussions. Can it work?
Can Fam Physician 2001 Mar 01;47:557-63
HSL2364
Belkin , L .
Prime time pushers
2001 Mar;31-37
http://motherjones.com/magazine/MA01/drug.html
HSL2542
Perkin R.
Why the PAAB is important
Annals RCPSC 2001 Mar;34:(2):105
HSL7820
White K, Beall T.
Changing OTC landscape
Pharmaceutical Executive 2001 Mar;21:82, 84, 86, 88, 90
HSL7821
Bernacchi T.
Challenge of prescription drug pricing
Pharmaceutical Executive 2001 Mar;21:56-58, 60, 62, 64, 66, 68
HSL15544
Morris LA, Pines WL.
Regulating Future Pharmaceutical Promotion.
Medical Marketing & Media 2001 Mar;36:(3):62
http://www.mmm-online.com/issuearchive/
HSL2019
Noonan D.
GM's War on Drug Costs.
Newsweek 2001 Feb 2646
HSL2363
GM's war on drugs
Newsweek 2001 Feb 26;46-48
HSL2349
Buffett L , McCormick W
Unwanted freebies
CMAJ 2001 Feb 20;164:(4):464
HSL2353
Gold , A .
A drug by any other name
CMAJ 2001 Feb 20;164:(4):464
HSL2354
Hoey , J .
A drug by any other name
CMAJ 2001 Feb 20;164:(4):464
HSL2562
Hoey J.
A drug by any other name (response)
Canadian Medical Association Journal 2001 Feb 20;164:(4):464
HSL2018
Jackson L.
Paying the Price
Australian Brodcasting Corporation: 4 Corners 2001 Feb 19
http://www.abc.net.au/4corners/stories/4Cprograms_PAYINGTHE.htm
HSL19534
Shapiro JP, Schultz S.
Prescriptions: how your doctor makes the choice.
US News World Rep 2001 Feb 19;130:(7):58-61
http://www.ncbi.nlm.nih.gov/pubmed/11225095
HSL19778
Hittmann G
Undue Influence?
Australian Doctor 2001 Feb 16
HSL19824
Reuters
Dietary Supplement Recalled for Containing Prescription Anxiety Drug
MedScape 2001 Feb 16
HSL2352
Weber W.
Sponsored continuing medical education under scrutiny in Europe
Lancet 2001 Feb 10;357:452
HSL8833
Gupta S.
Why le Carre’s ThreeBees will not sting India : Trust our immune system
Indian Express (Mumbai) 2001 Feb 10
http://www.expressindia.com/ie/daily/20010227/shekhar.htm
HSL20138
Mesley W
The battle over a drug ad
Undercurrents : CBC-TV 2001 Feb 40
HSL2362
Sibbald , B .
Doctors asked to take pledge to shun drug company freebies
CMAJ 2001 Feb 01;164:(4):531
HSL2351
Lal A.
Pharmaceutical drug promotion: how it is being practiced in India?
J Assoc Physicians India 2001 Feb;49:266-73:
HSL18009
McGettigan P, Golden J, Fryer J, Chan R, Feely J.
Prescribers prefer people: The sources of information used by doctors for prescribing suggest that the medium is more important than the message.
Br J Clin Pharmacol 2001 Feb;51:(2):184-9
http://www3.interscience.wiley.com/journal/118991090/abstract
HSL2350
Therapeutic Products Programme.
Advertising Standards Canada and the Therapeutic Product Programme's roles and consultation related to advertising review and complaint adjudication
2001 Jan 22;
http://www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/policy/issued/advcaf_e.pdf
HSL7835
Van Diepen LR.
Pharmaceutical manufacturer assistance programs for indigent patients: solution or symptom?
Am J Health Syst Pharm 2001 Jan 15;58:(2):162-3
http://www.ajhp.org/cgi/reprint/58/2/162
HSL7898
Mehl B, Santell J.
Projecting future drug expenditures--2001.
Am J Health Syst Pharm 2001 Jan 15;58:(2):125-33
http://www.ajhp.org/cgi/reprint/58/2/125
HSL7899
Weiner S, Dischler J, Horvitz C.
Beyond pharmaceutical manufacturer assistance: broadening the scope of an indigent drug program.
Am J Health Syst Pharm 2001 Jan 15;58:(2):146-50
http://www.ajhp.org/cgi/reprint/58/2/146
HSL7901
Kennedy A.
Additional Novartis products available through assistance programs
American Journal of Health System Pharmacy 2001 Jan 1;58:79
HSL4940
Jesani A.
Calls for advertising and market reforms in health care.
Issues Med Ethics 2001 Jan-Mar;9:(1):19
HSL4941
Mamdani B, Mamdani M.
Ethics of professional advertising.
Issues Med Ethics 2001 Jan-Mar;9:(1):18
HSL4942
Malpani A.
Doctors should be allowed to advertise.
Issues Med Ethics 2001 Jan-Mar;9:(1):16-7
HSL4943
Pandya SK.
Advertising remains unethical even in the digital age.
Issues Med Ethics 2001 Jan-Mar;9:(1):15
HSL7825
Cloutier M, Golenski J.
RxHealthValue offers three recommendations and cost research
Journal of Managed Care Pharmacy 2001 Jan-Feb;7:17-20
HSL7831
Ellen EF.
Visits From Pharmaceutical Reps
Psychiatric Times 2001 Jan;18:(1):
http://www.psychiatrictimes.com/p010121.html
HSL32
Woloshin S, Schwartz LM, Tremmel J, Welch HG
Direct-to-consumer advertisements for prescription drugs: what are Americans being sold?
Lancet 2001;358:1141-1146
http://linkinghub.elsevier.com/retrieve/pii/S0140673601062547
HSL34
Vlassov V, Mansfield P, Lexchin J, Vlassova A.
Do drug advertisements in Russian medical journals provide essential information for safe prescribing?
West J Med 2001;174:391-394
HSL36
Robinson J.
Prescription games: money, ego, and power inside the global pharmaceutical industry
Toronto: McClelland and Stewart 2001
http://www.amazon.co.uk/exec/obidos/ASIN/0771075685/qid=1124431439/sr=1-3/ref=sr_1_10_3/026-3368758-1517268
HSL37
Montaner JSG, O'Shaughnessy MV, Schechter MT.
Industry-sponsored clinical research: a double-edged sword
Lancet 2001;385:1893-1895
HSL38
Lill DJ, Peterson RT.
Older adult portrayal in television commercials by pharmaceutical manufacturers: an analysis
Journal of Pharmaceutical Marketing & Management 2001;14:(1):81-96
HSL39
Lewis S, Baird P, Evans RG, Ghali WA, Wright CJ, Gibson E, et al
Dancing with the porcupine: rules for governing the university-industry relationship
Can Med Assoc J 2001;165:783-785
http://www.cmaj.ca/cgi/content/full/165/6/783
HSL40
Kemmeren JM, Algra A, Grobbee DE.
Third generation oral contraceptives and risk of venous thrombosis: meta-analysis
BMJ 2001;323:131-134
http://bmj.bmjjournals.com/cgi/content/full/323/7305/131
HSL42
Gönül FF, Carter F, Petrova E, Srinivasan K.
Promotion of prescription drugs and its impact on physicians' choice behavior
Journal of Marketing 2001;65:79-90
HSL43
Findlay SD.
Direct-to-consumer promotion of prescription drugs: economic implications for patients, payers and providers
Pharmacoeconomics 2001;19:(2):109-199
HSL1819
Okoro EO, Davies AE.
Sponsorship of educational programmes in Nigerian medical and pharmacy schools by pharmaceutical companies: possible risk implication for public health.
Ethics Med 2001 Spr;17:(1):52-60
HSL2053
Ainslie G.
Breakdown of Will
Cambridge: Cambridge University Press 2001
http://www.cambridge.org/uk/catalogue/catalogue.asp?isbn=0521596947
HSL2156
Jureidini J, Mansfield P.
Does drug promotion adversely influence doctors’ abilities to make the best decisions for patients?
Australasian Psychiatry 2001;9:95-99
http://www.blackwell-synergy.com/doi/full/10.1046/j.1440-1665.2001.00313.x?prevSearch=allfield%3A%28Jureidini+J+and+Mansfield+P%29
HSL2192
Sponsorship, authorship and accountability
CMAJ 2001
HSL2278
Sterne J, Smith G.
Sifting the evidence -- what's wrong with significance tests?
BMJ 2001;322:226-231
http://bmj.bmjjournals.com/cgi/content/full/322/7280/226?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&author1=Sterne+J&andorexactfulltext=and&searchid=1124938332664_18808&stored_search=&FIRSTINDEX=0&sortspec=relevance&resourcetype=1
HSL2345
Consumers' Association
Policy report: promotion of prescription drugs: public health or private profit?
Consumers' Association 2001
HSL2346
Eichner , R MAROONICK, T J.
A review of direct-to-consumer (DTC) advertising and sales of prescription drugs: does DTC advertising increase sales and market share?
Journal of Pharmaceutical Marketing & Management 2001;13:(4):19-42
HSL2347
Mintzes B, Baraldi R .
Direct-to-consumer prescription drug advertising: when public health is no longer a priority
DES Action Canada 2001;
HSL2348
Rubin , Ph .
Pharmaceutical advertising as a consumer empowerment device
Journal of Biolaw & Business 2001;4:(4):59-65
HSL2551
Mintzes B, Baraldi R.
Direct to Consumer Prescription Drug Advertising: When preventing harm is no longer a priority
: DES Action Canada 2001;
http://web.archive.org/web/20011217054640/http://www.web.net/~desact/anglais/anglais.html
HSL2554
Meek C.
2001;
www.rpsgb.org.uk/pdfs/dtcarep.pdf
HSL2568
Consumers ASSOCIATION, .
dtca alliances organisations
2001;
HSL2571
Canadian Medical Association
CMA Policy: Physicians and the pharmaceutical industry (Update 2001)
2001;
www.cma.ca/staticContent/HTML/N0/l2/where_we_stand/physicians_and_the_pharmaceutical_industry.pdf
HSL5445
Rai AK.
The information revolution reaches pharmaceuticals: balancing innovation incentives, cost, and access in the post-genomics era.
Univ Ill Law Rev 2001;2001:(1):173-210
HSL7765
Baqir W, Maguire A.
Doctors' and pharmacists' attitudes to the use of sugar-free and sugar-containing medicines in the elderly
International Journal of Pharmacy Practice 2001;9:(3):177-184
HSL7768
DTC debate
Irish Pharmacy Journal 2001;79:(137-138):140
HSL7801
E-commerce in pharmacy: opportunity or threat?
Acta-Farmaceutica-Bonaerense 2001;9:(3):8-9, 16
HSL7804
Adachi T, Hara H, Hirano K.
Students' awareness about practical training in community prescription pharmacy
Japanese Journal of Pharmaceutical Health Care and Sciences 2001;27:(4):386-391
HSL7806
Barlas S.
FDA proposed ruling on package inserts
P-and-T 2001;26:259
HSL7809
Do Dear Health Care Professional letters make a difference?
Hospital Pharmacy 2001;36:928
HSL7810
McPherson D.
Sweet taste of success: Tom Greene has a sure fire prescription for smiles
Community Pharmacist 2001;93:(2):20-22
HSL7845
Framework for Research and Evaluation into the Effects of Managed Care on the Pharmaceutical Marketplace: excerpts from the final report
Journal of Research in Pharmaceutical Economics 2001;10:(4):235-266
HSL7890
Frenia KJ, Maves MD, Toscani MR.
Rx to OTC switching...issues and answers
ASHP Annual Meeting 2001;58:
HSL8831
Brynner R, Stephens T.
Dark Remedy: The Impact Of Thalidomide And Its Revival As A Vital Medicine
New York: Basic Books 2001
http://www.perseusbooksgroup.com/basic/book_detail.jsp?isbn=0738205907
HSL16336
Cohen JS
Overdose : The case against the drug companies – Prescription drugs, side effects and your Health New York: Tarcher/Putnam 2001
HSL18002
Monnet DL, Sorensen TL.
The patient, their doctor, the regulator and the profit maker: conflicts and possible solutions.
Clin Microbiol Infect 2001;7:
HSL18003
Holmes WF.
Conflicts of interest between the prescriber, the regulator and the profit maker.
Clin Microbiol Infect 2001;7:
HSL18175
Fava GA
Conflict of Interest and Special Interest Groups
Psychother Psychosom 2001;70:1-5
http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowFulltext&ArtikelNr=000056218&Ausgabe=228212&ProduktNr=223864
HSL19053
Woloshin S, Schwartz LM, Moncur M, Gabriel S, Tosteson AN.
Assessing values for health: numeracy matters.
Med Decis Making 2001;21:(5):382-90
http://www.ncbi.nlm.nih.gov/pubmed/11575488
HSL19054
Schwartz LM, Woloshin S.
The case for letting information speak for itself.
Eff Clin Pract 2001;4:(2):76-9
http://www.acponline.org/clinical_information/journals_publications/ecp/marapr01/schwartz.htm
HSL19396
Gonul F, Carter F, Petrova E, Srinivasan K
Promotion of prescription drugs and its impact on physicians' choice behaviour
J Marketing 2001;65: 79–90
http://www.atypon-link.com/AMA/doi/abs/10.1509/jmkg.65.3.79.18329
HSL19928
Mohr LA, Webb DJ, Harris KA
Do Consumers Expect Companies to be Socially Responsible? The Impact of Corporate Social Responsibility on Buying Behavior
Journal of Consumer Affairs 2001;35:(1):45
http://onlinelibrary.wiley.com/doi/10.1111/j.1745-6606.2001.tb00102.x/abstract
HSL19984
Harvey R
And on the cover of the Guide were two words in red - Don't Panic
Australian Health Review 2001;24:(2):15
http://www.publish.csiro.au/paper/AH010015.htm
HSL20109
Miller AR
Drugs: It's up to the public to complain
CMAJ 2001;165:(1):153
HSL20178
Hoek J, Gendall P, Feetham P
Could less be more? An Analysis of Direct to Consumer Advertising of Prescription Medicines
Marketing Bulletin 2001;12:(1):
marketing-bulletin.massey.ac.nz/V12/MB_V12_A1_Hoek.pdf
HSL20342
Dowie J
Decision analysis and the evaluation of decision technologies
BMJ 2001;10:(1):1-2
http://qualitysafety.bmj.com/content/10/1/1
HSL2262
Nuesch R, Dieterle T.
Industry-sponsored research.
Lancet 2000 Dec 23-30;356:(9248):2193-4
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11191572&query_hl=1
HSL2265
Halpern SD, Karlawish JH.
Industry-sponsored research. University of Pennsylvania Research Ethics Working Group.
Lancet 2000 Dec 23-30;356:(9248):2193
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11191573&query_hl=1
HSL2620
Neusch R.
Industry-sponsored research (2nd of two letters)
Lancet 2000 Dec 23-30;356:2193
HSL6973
Djulbegovic B, Bennett CL, Adams JR, Lyman GH.
Authors' reply
The Lancet 2000 Dec 23;356:(9248):2193
HSL6974
Giannakakis IA, Ioannidis JP.
Arabian nights-1001 tales of how pharmaceutical companies cater to the material needs of doctors: case report.
BMJ 2000 Dec 23-30;321:(7276):1563-4
http://www.bmj.com/cgi/content/full/321/7276/1563
HSL164
Willman D.
How a New Policy Led to Seven Deadly Drugs
The Los Angeles Times 2000 Dec 20
Page 162 of 206 pages ‹ First < 160 161 162 163 164 > Last ›
